
    
      Patients with relapsed /refractory diffuse large B cell lymphoma usually have a bad
      prognosis. These patients cannot be treated successfully with the conventional chemotherapy
      of CHOP. Apatinib is a new type of oral tyrosine kinase inhibitor targeting VEGFR-2.The
      investigators have been proceeding this trial to evaluate the efficacy and safety of Apatinib
      in the patients with relapsed refractory diffuse large B cell lymphoma.
    
  